Day One Biopharmaceuticals Stock Performance
| DAWN Stock | USD 12.07 0.04 0.33% |
Day One holds a performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.53, which means possible diversification benefits within a given portfolio. As returns on the market increase, Day One's returns are expected to increase less than the market. However, during the bear market, the loss of holding Day One is expected to be smaller as well. Use Day One downside variance, as well as the relationship between the accumulation distribution and price action indicator , to analyze future returns on Day One.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Day One Biopharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Day One displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.33) | Five Day Return 14.3 | Year To Date Return 36.38 | Ten Year Return (48.64) | All Time Return (48.64) |
1 | Day One Biopharmaceuticals Inc Q3 2025 Earnings Report Preview What To Expect | 11/03/2025 |
2 | Disposition of 3570 shares by Bender Jeremy of Day One subject to Rule 16b-3 | 11/14/2025 |
3 | Disposition of 15894 shares by Bender Jeremy of Day One at 8.9147 subject to Rule 16b-3 | 11/17/2025 |
4 | Acquisition by Bender Jeremy of 300000 shares of Day One subject to Rule 16b-3 | 11/26/2025 |
5 | Day One Biopharmaceuticals Sees Unusually-High Trading Volume Should You Buy | 12/11/2025 |
6 | Day One Biopharma Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA | 12/16/2025 |
7 | We Think Day One Biopharmaceuticals Can Easily Afford To Drive Business Growth | 12/19/2025 |
8 | Day One Biopharmaceuticals Nasdaq Index Biomarker Science | 01/02/2026 |
9 | Day One Biopharmaceuticals Stock Price Up 11.2 percent - Heres What Happened - MarketBeat | 01/07/2026 |
10 | A Look At Day One Biopharmaceuticals Valuation After Strong OJEMDA Revenue And 2026 Outlook Updates | 01/13/2026 |
11 | Day One Biopharmaceuticals Is Up 11.7 percent After Strong OJEMDA 2025 Sales And 2026 Outlook - Has The Bull Case Changed | 01/15/2026 |
12 | Optimistic Investors Push Day One Biopharmaceuticals, Inc. Shares Up 31 percent But Growth Is Lacking | 01/21/2026 |
| Begin Period Cash Flow | 230.8 M | |
| Total Cashflows From Investing Activities | -231 M |
Day One Relative Risk vs. Return Landscape
If you would invest 749.00 in Day One Biopharmaceuticals on October 24, 2025 and sell it today you would earn a total of 458.00 from holding Day One Biopharmaceuticals or generate 61.15% return on investment over 90 days. Day One Biopharmaceuticals is currently generating 1.019% in daily expected returns and assumes 6.9665% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Day, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Day One Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Day One's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Day One Biopharmaceuticals, and traders can use it to determine the average amount a Day One's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1463
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | DAWN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Day One is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Day One by adding it to a well-diversified portfolio.
Day One Fundamentals Growth
Day Stock prices reflect investors' perceptions of the future prospects and financial health of Day One, and Day One fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Day Stock performance.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (1.14) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 795.74 M | ||||
| Shares Outstanding | 102.68 M | ||||
| Price To Earning | 3.88 X | ||||
| Price To Book | 2.76 X | ||||
| Price To Sales | 9.30 X | ||||
| Revenue | 131.16 M | ||||
| Gross Profit | 119.56 M | ||||
| EBITDA | (86.32 M) | ||||
| Net Income | (95.5 M) | ||||
| Cash And Equivalents | 394.86 M | ||||
| Cash Per Share | 5.38 X | ||||
| Total Debt | 2.6 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 31.45 X | ||||
| Book Value Per Share | 4.39 X | ||||
| Cash Flow From Operations | (78.11 M) | ||||
| Earnings Per Share | (1.52) X | ||||
| Market Capitalization | 1.24 B | ||||
| Total Asset | 582.79 M | ||||
| Retained Earnings | (554.08 M) | ||||
| Working Capital | 488.88 M | ||||
About Day One Performance
By examining Day One's fundamental ratios, stakeholders can obtain critical insights into Day One's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Day One is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 206.66 | 183.70 | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.16) | (0.15) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about Day One Biopharmaceu performance evaluation
Checking the ongoing alerts about Day One for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Day One Biopharmaceu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Day One Biopharmaceu is way too risky over 90 days horizon | |
| Day One Biopharmaceu appears to be risky and price may revert if volatility continues | |
| Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 131.16 M. Net Loss for the year was (95.5 M) with profit before overhead, payroll, taxes, and interest of 119.56 M. | |
| Day One Biopharmaceuticals currently holds about 394.86 M in cash with (78.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38. | |
| Day One Biopharmaceu has a poor financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Erasca Insider Sells 671K as Stock Jumps 189 percent This Past Year |
- Analyzing Day One's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Day One's stock is overvalued or undervalued compared to its peers.
- Examining Day One's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Day One's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Day One's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Day One's stock. These opinions can provide insight into Day One's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.58) | Return On Assets | Return On Equity |
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.